# US 2003/0226155 A1 · Modified transferrin-antibody fusion proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0226155 A1
- Document ID: US20030226155A1
- Status: Published application
- Kind: A1
- Application number: 10/384,060
- Filed: 2003-03-10
- Published: 2003-12-04
- Earliest claimed: 2001-08-30
- Assignees: Biorexis Pharmaceutical Corporation
- Inventors: Homayoun Sadeghi; Christopher P. Prior; Andrew Turner
- Web page: https://patentgrep.com/patent/US20030226155A1

## CPC

- C12N 15/62: DNA sequences coding for fusion proteins
- A61K 47/644: {Transferrin, e.g. a lactoferrin or ovotransferrin}
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 39/00: General protective or antinoxious agents
- C07K 14/79: Transferrins, e.g. lactoferrins, ovotransferrins
- C07K 16/241: {Tumor Necrosis Factors}
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2318/20: Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
- C07K 2319/00: Fusion polypeptide
- C07K 2319/035: containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

Modified fusion proteins of transferrin and therapeutic proteins or peptides, preferably antibody variable regions, with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor.

## Claims

### Claim 1

A fusion protein comprising a transferrin (Tf) protein exhibiting reduced glycosylation fused to at least one antibody variable region.

### Claim 2 (depends on 1)

A fusion protein of claim 1, wherein the antibody variable region comprises a VH, VL, or a CDR region.

### Claim 3 (depends on 1)

A fusion protein of claim 1, comprising at least two antibody variable regions.

### Claim 4 (depends on 3)

A fusion protein of claim 3, comprising at least a VH and VL region, a VH and VH region, or a VL and VL region.

### Claim 5 (depends on 1)

A fusion protein of claim 1, comprising at least two different antibody variable regions.

### Claim 6 (depends on 5)

A fusion protein of claim 5, wherein the different antibody variable regions specifically bind different antigens.

### Claim 7 (depends on 3)

A fusion protein of claim 3, wherein the fusion protein is engineered so that the antibody variable regions are in close proximity.

### Claim 8 (depends on 7)

A fusion protein of claim 7, wherein the antibody variable regions are inserted into two adjacent Tf loops.

### Claim 9 (depends on 8)

A fusion protein of claim 8, wherein one antibody variable region is fused to the C-terminus of Tf and one antibody variable region is inserted into an adjacent Tf loop.

### Claim 10 (depends on 8)

A fusion protein of claim 8, wherein one antibody variable region is fused to the N-terminal end of Tf and one antibody variable region is inserted into an adjacent Tf loop.

### Claim 11 (depends on 9)

A fusion protein of claim 9, wherein the Tf C-terminal proline residue is deleted.

### Claim 12 (depends on 9)

A fusion protein of claim 9, wherein the Tf C-terminal cysteine loop is deleted.

### Claim 13 (depends on 8)

A fusion protein of claim 8, wherein the antibody variable regions are fused to the N- and C-terminal ends of Tf.

### Claim 14 (depends on 1)

A fusion protein of claim 1, wherein the antibody variable region comprises at least one CDR peptide.

### Claim 15 (depends on 14)

A fusion protein of claim 14, wherein the CDR peptide specifically binds an antigen.

### Claim 16 (depends on 14)

A fusion protein of claim 14, wherein the CDR peptide is derived from an antibody.

### Claim 17 (depends on 14)

A fusion protein of claim 14, wherein the CDR peptide is from a peptide library.

### Claim 18 (depends on 1)

A fusion protein of claim 1, wherein the antibody variable region specifically binds to tumor necrosis factor (TNF).

### Claim 19 (depends on 14)

A fusion protein of claim 14, wherein the CDR specifically binds to TNF.

### Claim 20 (depends on 1)

A fusion protein of claim 1, wherein the at least one antibody variable region comprises amino terminal domains of a VH or VL region of an antibody.

### Claim 21 (depends on 20)

A fusion protein of claim 20, wherein the amino terminal domain comprises at least one CDR.

### Claim 22 (depends on 21)

A fusion protein of claim 21, wherein the amino terminal domain comprises 3 CDRs.

### Claim 23 (depends on 1)

A fusion protein of claim 1, wherein the antibody variable region is fused to the C-terminal end of Tf.

### Claim 24 (depends on 1)

A fusion protein of claim 1, wherein the antibody variable region is fused to the N-terminal end of Tf.

### Claim 25 (depends on 1)

A fusion protein of claim 1, wherein the antibody variable region is inserted into at least one loop of the Tf.

### Claim 26 (depends on 1)

A fusion protein of claim 1, wherein the Tf protein has reduced affinity for a transferrin receptor (TfR).

### Claim 27 (depends on 1)

The fusion protein of claims 1, wherein the Tf protein is lacto transferrin (lactoferrin).

### Claim 28 (depends on 26)

A fusion protein of claim 26, wherein the Tf protein does not bind a TfR.

### Claim 29 (depends on 1)

A fusion protein of claim 1, wherein the Tf protein has reduced affinity for iron.

### Claim 30 (depends on 29)

A fusion protein of claim 29, wherein the Tf protein does not bind iron.

### Claim 31 (depends on 1)

A fusion protein of claim 1, wherein said Tf protein comprises at least one mutation that prevents glycosylation.

### Claim 32 (depends on 31)

A fusion protein of claim 31, wherein the Tf protein is lacto transferrin (lactoferrin).

### Claim 33 (depends on 1)

A fusion protein of claim 1, which is expressed in the presence of tunicamycin

### Claim 34 (depends on 1)

A fusion protein of claim 1, wherein said Tf protein comprises a portion of the N domain of a Tf protein, a bridging peptide and a portion of the C domain of a Tf protein.

### Claim 35 (depends on 34)

A fusion protein of claim 34, wherein the bridging peptide links the antibody variable region to Tf

### Claim 36 (depends on 34)

A fusion protein of claim 34, wherein the antibody variable region is inserted between an N and a C domain of Tf protein.

### Claim 37 (depends on 1)

A fusion protein of claim 1, wherein the Tf protein comprises at least one amino acid substitution, deletion or addition in the hinge region.

### Claim 38 (depends on 37)

A fusion protein of claim 37, wherein said hinge region is selected from the group consisting of about residue 94 to about residue 96, about residue 245 to about residue 247, about residue 316 to about residue 318, about residue 425 to about residue 427, about residue 581 to about residue 582 and about residue 652 to about residue 658.

### Claim 39 (depends on 1)

A fusion protein of claim 1, wherein said Tf protein has at least one amino acid substitution, deletion or addition at a position selected from the group consisting of Asp 63, Gly 65, Tyr 95, Tyr 188, Lys 206, His 207, His 249, Asp 392, Tyr 426, Tyr 514, Tyr 517, His 585, Thr 120, Arg 124, Ala 126, Gly 127, Thr 452, Arg 456, Ala 458 and Gly 459.

### Claim 40 (depends on 25)

A fusion protein of claim 25, wherein the antibody variable region replaces at least one loop of Tf.

### Claim 41 (depends on 31)

A fusion protein of claim 31, wherein the glycosylation site is selected from the group consisting of an amino acid residue corresponding to amino acids N413, N611.

### Claim 42 (depends on 26, 28)

A fusion protein of claim 26 or 28, wherein the Tf comprises at least one amino acid substitution, deletion or addition at an amino acid residue corresponding to an amino acid selected from the group consisting of Asp 63, Gly 65, Tyr 95, Tyr 188, Lys 206, His 207, His 249, Asp 392, Tyr 426, Tyr 514, Tyr 517, His 585, Thr 120, Arg 124, Ala 126, Gly 127, Thr 452, Arg 456, Ala 458 and Gly 459.

### Claim 43

A fusion protein comprising a transferrin (Tf) protein exhibiting reduced affinity for a transferrin receptor (TfR) fused to at least one antibody variable region.

### Claim 44 (depends on 43)

A fusion protein of claim 43, comprising at least two antibody variable regions.

### Claim 45 (depends on 44)

A fusion protein of claim 44, comprising at least a VH and VL region, a VH and VH region, or a VL and VL region.

### Claim 46 (depends on 43)

A fusion protein of claim 43, comprising at least two different antibody variable regions.

### Claim 47 (depends on 46)

A fusion protein of claim 46, wherein the different antibody variable regions specifically bind different antigens.

### Claim 48 (depends on 44)

A fusion protein of claim 44, wherein the fusion protein is engineered so that the antibody variable regions are in close proximity.

### Claim 49 (depends on 48)

A fusion protein of claim 48, wherein the antibody variable regions are inserted into two adjacent Tf loops.

### Claim 50 (depends on 49)

A fusion protein of claim 49, wherein one antibody variable region is fused to the C-terminus of Tf and one antibody variable region is inserted into an adjacent Tf loop.

### Claim 51 (depends on 49)

A fusion protein of claim 49, wherein one antibody variable region is fused to the N-terminal end of Tf and one antibody variable region is inserted into an adjacent Tf loop.

### Claim 52 (depends on 50)

A fusion protein of claim 50, wherein the Tf C-terminal proline residue is deleted.

### Claim 53 (depends on 50)

A fusion protein of claim 50, wherein the Tf C-terminal cysteine loop is deleted.

### Claim 54 (depends on 49)

A fusion protein of claim 49, wherein the antibody variable regions are fused to the N- and C-terminal ends of Tf.

### Claim 55 (depends on 43)

A fusion protein of claim 43, wherein the antibody variable region comprises at least one CDR peptide.

### Claim 56 (depends on 55)

A fusion protein of claim 55, wherein the CDR peptide specifically binds an antigen.

### Claim 57 (depends on 55)

A fusion protein of claim 55, wherein the CDR peptide is derived from an antibody. (???)

### Claim 58 (depends on 55)

A fusion protein of claim 55, wherein the CDR peptide is from a peptide library.

### Claim 59 (depends on 43)

A fusion protein of claim 43, wherein the antibody variable region specifically binds to tumor necrosis factor (TNF).

### Claim 60 (depends on 55)

A fusion protein of claim 55, wherein the CDR specifically binds to TNF.

### Claim 61 (depends on 43)

A fusion protein of claim 43, wherein the antibody variable region comprises amino terminal domains of a VH or VL region of an antibody.

### Claim 62 (depends on 61)

A fusion protein of claim 61, wherein the amino terminal domain comprises at least one CDR.

### Claim 63 (depends on 62)

A fusion protein of claim 62, wherein the amino terminal domain comprises 3 CDRs.

### Claim 64 (depends on 1, 43)

A fusion protein of claim 1 or 43, wherein the serum half-life of the antibody variable region is increased over the serum half-life of the antibody variable region in an unfused state.

### Claim 65 (depends on 43)

A fusion protein of claim 43, wherein the therapeutic protein or peptide is fused to the C-terminal end of Tf.

### Claim 66 (depends on 43)

A fusion protein of claim 43, wherein the therapeutic protein or peptide is fused to the N-terminal end of Tf.

### Claim 67 (depends on 43)

A fusion protein of claim 43, wherein the therapeutic protein or peptide is inserted into at least one loop of the Tf.

### Claim 68 (depends on 43)

A fusion protein of claim 43, wherein the TF protein does not bind a TfR.

### Claim 69 (depends on 43)

A fusion protein of claim 43, wherein the Tf protein has reduced affinity for iron.

### Claim 70 (depends on 69)

A fusion protein of claim 69, wherein the Tf protein does not bind iron.

### Claim 71 (depends on 43)

A fusion protein of claim 43, wherein said Tf protein exhibits reduced or no glycosylation.

### Claim 72 (depends on 71)

A fusion protein of claim 71, comprising at least one mutation that prevents glycosylation.

### Claim 73 (depends on 43)

A fusion protein of claim 43, wherein said Tf protein comprises a portion of the N domain of a Tf protein, a bridging peptide and a portion of the C domain of a Tf protein.

### Claim 74 (depends on 73)

A fusion protein of claim 73, wherein the bridging peptide links the therapeutic protein or peptide to Tf.

### Claim 75 (depends on 73)

A fusion protein of claim 73, wherein said therapeutic protein, peptide or polypeptide is inserted between an N and a C domain of Tf protein.

### Claim 76 (depends on 43)

A fusion protein of claim 43, wherein the Tf protein have at least one amino acid substitution, deletion or addition in the Tf hinge region.

### Claim 77 (depends on 76)

A fusion protein of claim 76, wherein said hinge region is selected from the group consisting of about residue 94 to about residue 96, about residue 245 to about residue 247, about residue 316 to about residue 318, about residue 425 to about residue 427, about residue 581 to about residue 582 and about residue 652 to about residue 658.

### Claim 78 (depends on 43)

A fusion protein of claim 43, wherein said Tf protein has at least one amino acid substitution, deletion or addition at a position selected from the group consisting of Asp 63, Gly 65, Tyr 95, Tyr 188, Lys 206, His 207, His 249, Asp 392, Tyr 426, Tyr 514, Tyr 517, His 585, Thr 120, Arg 124, Ala 126, Gly 127, Thr 452, Arg 456, Ala 458 and Gly 459.

### Claim 79 (depends on 67)

A fusion protein of claim 67, wherein the therapeutic protein or peptide replaces at least one loop.

### Claim 80 (depends on 71)

A fusion protein of claim 71, wherein the glycosylation site is selected from the group consisting of an amino acid residue corresponding to amino acids N413, N611.

### Claim 81 (depends on 1, 43)

A nucleic acid molecule encoding a fusion protein of either claim 1 or 43.

### Claim 82 (depends on 81)

A vector comprising a nucleic acid molecule of claim 81.

### Claim 83 (depends on 82)

A host cell comprising a vector of claim 82.

### Claim 84 (depends on 81)

A host cell comprising a nucleic acid molecule of claim 81.

### Claim 85 (depends on 83)

A method of expressing a Tf fusion protein comprising culturing a host cell of claim 83 under conditions which express the encoded fusion protein.

### Claim 86 (depends on 84)

A method of expressing a Tf fusion protein comprising culturing a host cell of claim 84 under conditions which express the encoded fusion protein.

### Claim 87 (depends on 83)

A host cell of claim 83, wherein the cell is prokaryotic or eukaryotic.

### Claim 88 (depends on 84)

A host cell of claim 84, wherein the cell is prokaryotic or eukaryotic.

### Claim 89 (depends on 87)

A host cell of claim 87, wherein the cell is a yeast cell.

### Claim 90 (depends on 88)

A host cell of claim 88, wherein the cell is a yeast cell.

### Claim 91

A transgenic animal comprising a nucleic acid molecule of 81.

### Claim 92 (depends on 91)

A method of producing a Tf fusion protein comprising isolating a fusion protein from a transgenic animal of claim 91.

### Claim 93 (depends on 92)

A method of claim 92, wherein the Tf fusion protein comprises lactoferrin.

### Claim 94 (depends on 93)

A method of claim 93, wherein the fusion protein is isolated from a biological fluid from the transgenic animal.

### Claim 95 (depends on 93)

A method of claim 93, wherein the fluid is serum or milk.

### Claim 96 (depends on 1, 43)

A method of treating a disease or disease symptom in a patient, comprising the step of administering a fusion protein of claim 1 or claim 43.

### Claim 97 (depends on 1, 43)

The fusion protein of claim 1 or claim 43, wherein the Tf protein has a N-terminal domain at each end of the protein.

### Claim 98 (depends on 97)

The fusion protein of claim 97, wherein the antibody variable region is fused to each N-terminal domain of the Tf protein.

### Claim 99 (depends on 1, 43)

The fusion protein of claim 1 or claim 43, wherein the antibody variable region binds specifically to a toxin.

### Claim 100 (depends on 96)

A method of claim 96, wherein the antibody variable regions binds to TNF.

### Claim 101 (depends on 100)

A method of claim 100, wherein the disease is selected from the group consisting of septic shock; endotoxic shock; cachexia syndromes associated with bacterial infections, viral infection, parasite infection, neoplastic disease; autoimmune disease, arthritis, and adverse effects associated with treatment for the prevention of graft rejection.
